Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265784 · ClinicalTrials.gov registry record · Phase 2
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
A Phase 2 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT01265784 is a Phase 2 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 143 participants.
The verdict
NCT01265784, a Phase 2 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).
Interventions
- DRUG Placebo
- DRUG Ertapenem
- DRUG TP-434
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265784
The ClinicalTrials.gov registry entry for NCT01265784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01265784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265784 about?
NCT01265784 is a clinical study titled "Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections". This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).
What is the current status of trial NCT01265784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2011-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01265784?
The interventions under investigation include: Placebo (DRUG), Ertapenem (DRUG), TP-434 (DRUG).
Who is sponsoring clinical trial NCT01265784?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.